Clinical Trials Browser

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

NCT02450656 2018-08-27

M14AFS

Phase 1/2 Unknown

320 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02975141 2018-08-13

AFFECT

Phase 1 Unknown

12 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03486509 2018-04-03

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

Phase 2 Unknown

2 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT01728818 2017-07-19

ACCEPT

Phase 2 Unknown

119 enrolled

Focus of Study Instead

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2 Unknown

188 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02511847 2016-04-15

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Phase 2 Unknown

40 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Phase 1/2 Unknown

50 enrolled

Thoracic

NSCLC

NCT01776684 2013-01-28

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Phase NA Unknown

200 enrolled

Thoracic

EGFR Mutation Positive Non-small Cell Lung Cancer

Clinical Trials

UPSTREAM

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

DPTA

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

TRUMP

Efficacy and Safety of Precision Therapy in Refractory Tumor

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

BELLA

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

HER2BAT

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

M14AFS

AFFECT

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

ACCEPT

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Afatinib Plus Nimotuzumb for NSCLC

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis